Forty specialists were asked about their management of three theoretical patients with advanced cancer of the head and neck. Reasons for variation were explored by considering the influence of perceived aims of treatment (radical or palliative), together with a number of factors relating to the tumour, the lymph nodes, and the patients' personal circumstances. The perceived aim of treatment was the most important determinant as to treatment modality but, when chances of influencing survival were small, there was disagreement as to the appropriate aim and subjective value judgements became influential. More careful analysis of the initial decision-making process is needed if new clinical trials are to significantly affect clinical practices.
Introduction
Advanced squamous cell cancer of the head and neck presents a challenge to the clinician. The disease tends to remain localized at the primary site and cervical lymph nodes but, despite advances in surgical and radiotherapeutic techniques, cure is exceptional.
It is well known that methods of treatment vary, but it is difficult to extract from current literature the reasons for this variation.
In this study, 40 clinicians with experience in treating patients with head and neck cancer were asked to indicate how they would treat three cases with advanced disease. Reasons for variation were then explored by asking about the aims of treatment (radical or palliative), expected survival, facilities and training for each doctor, together with the importance placed on a number offactors relating to the tumour, nodes. distant metastases and the patients' personal circumstances, when deciding whether or not to attempt curative therapy.
Method
Forty practitioners were questioned, 20 of whom were radiotherapists and 20 surgeons (14 otolaryngologists and three each of plastic and maxillo-facial surgeons). The questioning was conducted by us (EJM and AFJ).
The most frequent source of referral of patients with advanced head and neck cancer for all radiotherapists was an ENT surgeon whereas for surgeons it was the family practitioner for 55%, or a colleague in his own specialty in 40%. One plastic surgeon had the majority of his referrals from a general surgeon.
All those questioned had regular joint clinics with surgical or radiotherapy colleagues and a majority (83%) held at least one session in a District General Hospital, including 14 (70%)of surgeons and 19 (95%) of radiotherapists. In addition. 60% worked in undergraduate teaching hospitals, including 80% of the radiotherapists and 40% of the surgeons and 45% worked in postgraduate teaching hospitals, including 50% of the radiotherapists and 40% of the surgeons.
All respondents were asked how they would manage three cases with advanced head and neck cancer; their expectations of success and any reasons which would cause them to change their management.
The cases were presented as shown in Table 1 . Potentially influential factors were arranged under the headings of patient factors (age, general condition, social circumstances, smoking and drinking habits, distance from centre, existence of medical relative), tumour factors (size, site, macroscopic appearance, microscopic appearance, other tissues invaded) and nodal factors (size, site, laterality, fixity).
Results
A plan of management was suggested for all three cases by 39 specialists with 119 evaluable management plans; only one surgeon felt unable to make a plan for case 1 using the information provided.
Poor prognosis was acknowledged, with less than 20% chance of cure estimated in 75% of instances. As expected, there were a wide variety of treatment modalities suggested ( Table 2) .
Surgeons were slightly more optimistic than radiotherapists (see Table 2 ). They were also more inclined to propose a radical approach and less to withhold active treatment. Of the 73 radical treatments, 39 were proposed by surgeons, while ofthe 10 instances where supportive therapy alone would be offered six were suggested by radiotherapists. Surgeons were less likely to use chemotherapy than radiotherapists in any situation (11 vs 22), more likely to use surgery (41 vs 21), but equally likely to use radiotherapy (39 vs 38).
Prognosis was influential in the decision-making process. As perceived prognosis deteriorated, there was increasing disagreement as to whether the patient should be treated radically, palliatively, or given no treatment: eg with patient 1, where there was least consensus on management (T4 N2 carcinoma of the peripheral fossa). while 23 would treat radically, 11 palliatively and 6 would give supportive treatment alone: while for case 2, where over 50% of respondents estimated a more than 20% chance of cure, 37 would give radical treatment and no-one would withhold active therapy.
Perhaps the most influential determinant of mode of therapy was whether or not the aim of treatment was perceived to be radical or palliative. If the aim was radical the most popular option was a combination of radiotherapy and surgery (37 instances, six combined with chemotherapy) followed by radiotherapy without surgery (16 instances, 10 combined with chemotherapy) (2 and 3); but if treatment was designated as palliative, radiotherapy alone was the most popular option (20 out of 36), followed by chemotherapy alone!', Multi-modality of therapy was proposed less often than for radical therapy (3 out of 36 vs 48 out of 73), surgery was less favoured (57 vs 8) and lower doses of radiothe,rapy were used: eg for the 53 radical treatments involving radiotherapy, suggested doses were 50-70 Gy and 20-35 treatments in all cases, while 17 out of 23 palliative treatments involved doses of 20-30 Gy in 5-10 treatments. It is thus important to establish how patients are selected for 'curative' therapy.
Factors influencing the aim of treatment were also investigated. The importance of TNM staging in influencing management plans was relatively noncontroversial. All respondents agreed that the size of tumour would influence management; over 80% indicated that the site and invasiveness ofthe tumour would as well. Nodal factors, including size, site, laterality and fixity of the nodes, would cause over 75% to alter their management. Metastatic disease would stop 95% from treating radically, although two surgeons indicated that they could think of circumstances where they might still treat radically, even in the presence of metastatic disease. There was some disagreement as to the importance of the more subjective patient-related factors. This was illustrated when radiotherapists were asked to arrange suggested patient-related factors in order of importance (results shown in Tables 4 and 5 ). There was a variation in the specific age which would change a decision and while the level of social support was considered to be one of the three most important factors affecting whether or not cure was attempted for 30%, 50% would not take it into consideration at all.
Discussion
There are well-established controversies about the treatment of head and neck cancer including, amongst others, the timing of radiotherapy and surgery, their particular value in different conditions, the value of chemotherapy and the fractionation of radiotherapy. These controversies are reflected in the variety of approaches to therapy in the three cases (Tables 2 and 3 ). The three patients presented for consideration all had advanced disease with a poor prognosis. Each had cervical nodes greater than 3 em in diameter, which were fixed in cases 1 and 2. In published series, the presence of nodes considerably worsens the prognosis. For example in the tongue, 2 year survival for patients presenting with fixed nodes are less than 20%1,2. The picture is even bleaker in hypopharangeal and tonsillar cancer.
For case 1, surgically radical treatment would entail a bilateral neck dissection and pharyngolaryngectomy, with possible reconstruction with transposed viscus. Radical radiotherapy would involve treatment of the whole neck, as well as the primary site over a [4] [5] [6] [7] week period. Both procedures are associated with very considerable morbidity, for a patient seen to have an 80% chance of dying within a year. Similarly, for patient 3, with recurrent carcinoma in the tonsil and contralateral neck, the majority of those advocating radical treatment would include surgery. This would entail, at the least, resection of the primary site and a left radical neck dissection, together with reconstruction of the surgical defect in the pharynx.
The study highlights a well-known difficulty in the management of the patient with advanced head and neck cancer. The outlook for the majority of patients is extremely poor, but a minority may be cured, by doses of radiotherapy and surgical procedures associated with significant treatment-related morbidity. Thus the majority of patients may suffer considerable treatment-related toxicity and yet die of their disease within months of its completion. This raises an ethical problem, for should toxic, expensive, but potentially curative treatment be given, ifthere is so small a chance that this can be achieved? Supportive treatment only was suggested in only 10% of instances, even when, as in case 1,95% estimated that the patient would be dead within a year, reflecting the desire of doctors to offer treatment.
Currently, reporting the outcome of different types of management in head and neck cancer tends to focus on mortality, recurrence, or evidence of metastases. These are relatively easily measured and do not involve value judgements. However, survival alone may not indicate success from the patients' point of view. They may want to make a 'trade-off between quality and quantity of remaining life. In a study which emphasizes this", healthy volunteers were asked whether, if they had T3laryngeal cancer, they would prefer a laryngectomy, with 60% chance of cure but problems with speech, or radiotherapy, with a 30-50% chance of cure, but the chance of a normal voice. Twenty per cent indicated that they would prefer radiotherapy, indicating a preference for quality rather than quantity of life. On the other hand, another study" indicated that patients would undergo chemotherapy with toxic side-effects, if there was even a 20% chance of cure. Although there is increasing awareness that quality of life must be considered when evaluating a particular treatment", suitable instruments are notoriously difficult to design. The most widely used Karnofsky and WHO scales concentrate on general physical aspects with low values characteristic in patients dying from cancer, including head and neck cancer", but there are no specifically developed and proven quality of life indices which enable two treatments to be compared.
The data from this study confirmed data from other studies that the stated aim of treatment appears to be an important determinant as to the treatment modality suggested; that, when chances of influencing survival are small, there is disagreement about the appropriate aims; and, as the perceived prognosis deteriorates, subjective value judgements are ' more influential. For example, in this study, while there was agreement on the importance of tumour and node size, site and invasion, there was less agreement on the more subjective patient-related factors. Age and general condition were likely to influence decision making for the majority. Most commented that 'biological age' was more important than actual age, but when pressed, specialists appeared to have age 'cut-offs', all other factors being equal (see Table 5 ). There was also division of opinion on whether social support was important in influencing their decision, 30% indicating that it was one of the three most important patient-related factors, whereas 50% said they would not take it into consideration at all ( Table 5 ). Such factors appear to be influential in the treatment of other cancers, for example, a recent report studying patterns of treatment oflung cancer in the USA indicated that there was a significant difference in the chances of receiving treatment depending on the marital state of the patient".
In the UK head and neck cancer is relatively uncommon, evaluation of new therapies can only be made through multi-centred clinical trials. Patient accrual in such trials is notoriously slow. This study suggests that there may be significant exclusion of some patients based on subjective value judgements, thus reducing the numbers of patients entered into such clinical trials and also making the study unrepresentative of treatments of that condition and producing a bias which will be difficult to elucidate through stratification. It has been suggested that surrogate patient studies of this type may be helpful in clarifying physician bias, elucidating present patterns of practice, and designing clinical trials likely to attract a large patient accrual". It would be misleading to draw firm conclusions from this study, as it has evident limitations. We conducted the questioning ourselves, introducing a possible bias; geographically the majority (25) of respondents came from the south of the UK with only 15 from Scotland, the north and the midlands. The case histories were abbreviated and real patients giving their own histories might have led respondents to different plans of management. Although the total number questioned was small, the group were carefully targeted and the relatively few doctors in the treatment of advanced cancer of the head and neck in the United Kingdom support the use of small samples'". We contend that analysis of the decision-making process may be helpful in designing clinical trials, which will significantly affect clinical practice.
